Seroatlas · Human Serome Atlas

TMEM106B

Transmembrane protein 106B

Also known as: FLJ11273, MGC33727, T106B_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NUM4
Gene: TMEM106B
Ensembl: ENSG00000106460
Chromosome: 7
Canonical length: 274 aa
Protein class: Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location: Endosomes,Lysosomes

OverviewNCBI Gene

Enables ATPase binding activity. Involved in dendrite morphogenesis and lysosome localization. Located in endosome and lysosomal membrane. Implicated in hypomyelinating leukodystrophy 16. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

274 residues, UniProt reviewed canonical sequence.

>Q9NUM4|TMEM106B
     1  MGKSLSHLPL HSSKEDAYDG VTSENMRNGL VNSEVHNEDG RNGDVSQFPY VEFTGRDSVT
    61  CPTCQGTGRI PRGQENQLVA LIPYSDQRLR PRRTKLYVMA SVFVCLLLSG LAVFFLFPRS
   121  IDVKYIGVKS AYVSYDVQKR TIYLNITNTL NITNNNYYSV EVENITAQVQ FSKTVIGKAR
   181  LNNITIIGPL DMKQIDYTVP TVIAEEMSYM YDFCTLISIK VHNIVLMMQV TVTTTYFGHS
   241  EQISQERYQY VDCGRNTTYQ LGQSEYLNVL QPQQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TMEM106B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 48 nTPM

Expression across tissuesHPA

Tissue

liver: 48 nTPM
thyroid gland: 44 nTPM
adrenal gland: 44 nTPM
kidney: 41 nTPM
smooth muscle: 37 nTPM
placenta: 37 nTPM

Single-cell type

syncytiotrophoblasts: 207 nCPM
lacrimal acinar cells: 151 nCPM
corticotrophs: 123 nCPM
prostatic glandular cells: 111 nCPM
oligodendrocyte progenitor cells: 107 nCPM
adrenal cortex cells: 106 nCPM

Immune cell

naive CD4 T-cell: 26 nTPM
NK-cell: 23 nTPM
MAIT T-cell: 20 nTPM
naive CD8 T-cell: 19 nTPM
basophil: 17 nTPM
T-reg: 16 nTPM

Brain region

white matter: 73 nTPM
spinal cord: 66 nTPM
cerebellum: 59 nTPM
hypothalamus: 59 nTPM
pons: 55 nTPM
cerebral cortex: 54 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TMEM106B.

Disease | AllUniProt

Conditions TMEM106B is implicated in, by any mechanism.

Frontotemporal dementia 2 (FTD2) MIM:607485
Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 (FTDALS1) MIM:105550
Leukodystrophy, hypomyelinating, 16 (HLD16) MIM:617964

Disease | GeneticClinVar

2 pathogenic / likely-pathogenic of 131 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Leukodystrophy, hypomyelinating, 16

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.6
gnomAD pLI: 0.33
gnomAD missense Z: 0.92
DepMap mean gene effect: 0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ATPase binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TMEM106B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TMEM106B as an antibody target. Whether an autoantibody or antibody against TMEM106B could matter depends on whether native TMEM106B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TMEM106B is annotated at the cell surface, where native TMEM106B is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TMEM106B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...